Elisabeth Luporsi1,2, Alain Toledano3, Dominique Spaeth4, Florian Scotté5, Marc Espié6, Stéphanie Perot7, Ladan Duvillié8, Isabelle Pithois Merli8, Roland Bugat9. 1. Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France. e.luporsi@nancy.unicancer.fr. 2. Oncologue médical, Biostatisticien, Généticien, PMSI Oncomed, Coordination réseau lorrain GENECAL, Institut de Cancérologie de Lorraine Alexis Vautrin, Avenue de Bourgogne, F 54511, Vandoeuvre-Les-Nancy, France. e.luporsi@nancy.unicancer.fr. 3. American Hospital of Paris, Neuilly-sur-Seine, France. 4. Centre d'Oncologie de Gentilly, Nancy, France. 5. Hôpital Européen Georges-Pompidou, Paris, France. 6. Hôpital Saint Louis, Paris, France. 7. ICTA, Fontaine-les-Dijon, France. 8. Vifor Pharma, Cedex, Neuilly-sur-Seine, France. 9. Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.
Abstract
PURPOSE: This report describes the results of an observational, retrospective cohort study, evaluating the use of iron sucrose (IS) and red blood cell (RBC) transfusions in patients with cancer in routine clinical practice in France. A parallel investigated cohort treated with ferric carboxymaltose (FCM) has been reported earlier. METHODS: Data of patients with a solid tumour or haematological malignancy who have received IS or an RBC transfusion during 2010 from 3 months prior (M-3) to 3 months post first treatment (M+3) were analysed. RESULTS: Data from 46 patients who had received IS (400 mg median total iron dose) and 357 patients who had received RBC transfusions as first treatment (baseline) were included. Median haemoglobin levels improved from 9.9 g/dL (interquartile range 9.2; 11.0 g/dL) at baseline to 12.4 g/dL (11.4; 13.1 g/dL) at M+3 in IS-treated patients and from 8.2 g/dL (7.8; 8.8 g/dL) at baseline to 10.1 g/dL (8.8; 11.1 g/dL) in transfused patients. An erythropoiesis-stimulating agent was given to 54.3 and 28.9% of patients in the IS and the RBC transfusion groups, respectively, resulting in slightly better mean haemoglobin increase in both groups (2.4 vs 1.5 g/dL and 2.0 vs 1.6 g/dL, respectively). No severe nor serious adverse reaction and no hypersensitivity reactions were reported. CONCLUSION: Both IS and RBC transfusions effectively increased Hb levels in patients with cancer. IS was safe and well tolerated in this population. Considering prior reported results with FCM, using FCM may reduce ESA dose requirements and the required number of infusions.
PURPOSE: This report describes the results of an observational, retrospective cohort study, evaluating the use of iron sucrose (IS) and red blood cell (RBC) transfusions in patients with cancer in routine clinical practice in France. A parallel investigated cohort treated with ferric carboxymaltose (FCM) has been reported earlier. METHODS: Data of patients with a solid tumour or haematological malignancy who have received IS or an RBC transfusion during 2010 from 3 months prior (M-3) to 3 months post first treatment (M+3) were analysed. RESULTS: Data from 46 patients who had received IS (400 mg median total iron dose) and 357 patients who had received RBC transfusions as first treatment (baseline) were included. Median haemoglobin levels improved from 9.9 g/dL (interquartile range 9.2; 11.0 g/dL) at baseline to 12.4 g/dL (11.4; 13.1 g/dL) at M+3 in IS-treated patients and from 8.2 g/dL (7.8; 8.8 g/dL) at baseline to 10.1 g/dL (8.8; 11.1 g/dL) in transfused patients. An erythropoiesis-stimulating agent was given to 54.3 and 28.9% of patients in the IS and the RBC transfusion groups, respectively, resulting in slightly better mean haemoglobin increase in both groups (2.4 vs 1.5 g/dL and 2.0 vs 1.6 g/dL, respectively). No severe nor serious adverse reaction and no hypersensitivity reactions were reported. CONCLUSION: Both IS and RBC transfusions effectively increased Hb levels in patients with cancer. IS was safe and well tolerated in this population. Considering prior reported results with FCM, using FCM may reduce ESA dose requirements and the required number of infusions.
Entities:
Keywords:
Intravenous iron - Iron sucrose; Patients; RBC transfusion
Authors: D B Van Wyck; G Cavallo; B S Spinowitz; R Adhikarla; S Gagnon; C Charytan; N Levin Journal: Am J Kidney Dis Date: 2000-07 Impact factor: 8.860
Authors: Daan J A Crommelin; Jon S B de Vlieger; Vera Weinstein; Stefan Mühlebach; Vinod P Shah; Huub Schellekens Journal: AAPS J Date: 2013-09-25 Impact factor: 4.009
Authors: Bernard Favrat; Katharina Balck; Christian Breymann; Michael Hedenus; Thomas Keller; Anna Mezzacasa; Christoph Gasche Journal: PLoS One Date: 2014-04-21 Impact factor: 3.240